Global Pharmaceutical & Vaccines Leader
Innovation-Driven Growth Strategy
GSK plc stands as one of the world's leading pharmaceutical and vaccines companies, with a rich history dating back to 1715 and a portfolio spanning respiratory diseases, oncology, HIV, and innovative vaccines. Following its strategic demerger of the consumer healthcare business (Haleon) in 2022, GSK has sharpened its focus on biopharmaceutical innovation, delivering strong growth momentum across its core therapeutic areas.
GSK's Arexvy achieved 82.6% efficacy in preventing RSV-LRTD in adults 60+, with 94%+ efficacy in high-risk populations. The vaccine demonstrated 60-65% reduction in RSV-related hospitalizations, establishing GSK as the first-to-market leader in adult RSV protection.
GSK's strategy centers on four core therapeutic areas: respiratory/immunology & inflammation, oncology, HIV, and infectious diseases. The company is targeting over £12 billion in sales from new products and line extensions by 2026, with 14 new medicines and vaccines in development aiming for multi-blockbuster potential by 2031.
GSK operates through two primary segments: Commercial Operations and Total R&D. The company offers specialty medicines across oncology, respiratory/immunology, inflammation, and HIV, alongside a comprehensive vaccine portfolio protecting against shingles, meningitis, RSV, influenza, hepatitis, HPV, and other infectious diseases.
| Business Area | Key Products/Therapies | Strategic Focus |
|---|---|---|
| Specialty Medicines | Oncology (Blenrep), Respiratory (Nucala), Immunology | High-value, patent-protected therapies |
| Vaccines | Arexvy (RSV), Shingrix, Menveo, Fluarix | Innovation leadership, global access |
| HIV | Via ViiV Healthcare joint venture | Long-acting therapies, prevention |
| General Medicines | Asthma, COPD, bacterial infections | Established portfolio optimization |
GSK has strategic collaborations with CureVac for mRNA vaccine development and AN2 Therapeutics for tuberculosis therapies. The company's global reach extends across Europe, North America, Asia, and emerging markets, with a commitment to making over 2 million doses of its long-acting injectable cabotegravir LA PrEP available to low- and middle-income countries between 2025-2026.
GSK's heritage reflects centuries of scientific advancement and strategic evolution, positioning the company as a leader in pharmaceutical innovation:
| Year | Milestone | Impact |
|---|---|---|
| 1957 | Beecham researchers isolated penicillin nucleus 6-APA | Enabled development of new antibiotics including Amoxil |
| 1981 | Glaxo launched Zantac | Global blockbuster anti-ulcer treatment |
| 1987 | Burroughs Wellcome developed effective HIV treatment | Breakthrough in HIV epidemic management |
| 2000 | Glaxo Wellmerge and SmithKline Beecham merger | Created one of world's largest pharma companies |
| 2009 | ViiV Healthcare established with Pfizer and Shionogi | Specialized HIV company focused on innovation |
| 2018 | RTS,S malaria vaccine WHO recommendation | World's first malaria vaccine candidate |
| 2022 | Haleon consumer healthcare demerger | Focused strategy on biopharmaceuticals |
| 2023 | Arexvy FDA approval - first RSV vaccine for older adults | Breakthrough in adult infectious disease prevention |
GSK delivered solid financial performance in 2024 with total revenue of £31.38 billion, representing 3.46% growth year-over-year. The company maintained strong gross margins of 71.16% and continues to invest significantly in R&D to drive future growth.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenue | $31,376 | $30,328 | $29,324 |
| Gross Profit | $22,328 | $21,763 | $19,770 |
| Operating Income | $4,021 | $6,745 | $6,433 |
| Net Income | $2,575 | $4,928 | $14,956 |
| Operating Cash Flow | $8,206 | $8,624 | $8,941 |
| Gross Margin | 71.16% | 71.76% | 67.42% |
Net income declined in 2024 primarily due to the Zantac litigation, which impacted operating profit. However, underlying business performance remained robust, with specialty medicines sales growing by 19% and vaccines showing continued strength.
GSK invested £6.4 billion ($8.6 billion) in research and development in 2024, representing approximately 20.4% of revenue. This substantial investment underscores the company's commitment to innovation and pipeline development, with expectations for even greater R&D spending in 2025.
GSK aims to launch 14 new medicines and vaccines with multi-blockbuster potential (defined as >$1B annual sales) by 2031. The pipeline prioritizes best-in-class or first-in-class opportunities across four core therapeutic areas, with 37 programs in Phase 3 or registration as of early 2024.
Therapeutic Focus Areas:
Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) represents a landmark achievement in adult vaccine development, becoming the first FDA-approved RSV vaccine for adults 60 years and older. The vaccine has demonstrated exceptional efficacy in preventing RSV-related lower respiratory tract disease (LRTD).
Data from pivotal Phase 3 trial with 25,000+ participants aged 60+
Market Expansion: Arexvy has achieved increasing sales contributions from Europe and international markets, with launches in Japan (Q3 2024), Spain, and Italy (Q1 2025). GSK established its first vaccine distribution center in the Middle East in Abu Dhabi (July 2025), strengthening regional supply chain capabilities.
Safety Profile: Arexvy demonstrated a favorable safety profile with local injection site pain occurring in approximately 26% of recipients, systemic adverse events in 8-10%, and serious adverse events in <1% of cases—comparable to placebo groups.
GSK's oncology portfolio is anchored by Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC) for multiple myeloma that has demonstrated significant clinical benefit in relapsed/refractory settings.
As of early 2024, GSK's pipeline comprised 85 programs, with 37 in Phase 3 or undergoing registration. The company anticipates at least five significant new product approvals from the FDA in 2025.
| Product | Indication | Status |
|---|---|---|
| Penmenvy | Meningitis vaccine | FDA approved Q1 2025 |
| Blujepa | Uncomplicated UTIs | FDA approved Q1 2025 |
| Nucala | COPD | Under review |
| Blenrep | Multiple myeloma (earlier lines) | FDA approved Oct 2025 |
| Depemokimab | Severe asthma | Under review |
Digital Innovation Integration: GSK is actively embracing AI and machine learning to accelerate drug discovery, streamline clinical trials, and enhance manufacturing efficiency. The Q Block smart manufacturing facility in the UK uses AI-enabled systems to optimize production, while strategic partnerships with Cloud Pharmaceuticals and the IE School of Science and Technology accelerate AI-driven health solutions development.
GSK's growth strategy is built on three pillars: pipeline prioritization, geographical expansion, and strategic partnerships. The company is targeting sales exceeding £40 billion by 2031, driven by innovation in high-margin therapeutic areas.
Technology & Innovation Investment:
Intellectual Property Management: In April 2025, GSK and Pfizer finalized a global settlement concerning RSV patents, securing a royalty stream for GSK on sales of Abrysvo, demonstrating effective IP strategy execution.
GSK is well-positioned to capitalize on demographic trends driving healthcare demand, with a strong portfolio addressing aging populations, infectious disease prevention, and cancer treatment. The company's first-mover advantage in RSV vaccines and robust oncology pipeline provide multiple growth drivers.
| Metric | 2024 Actual | 2025 Guidance | 2026+ Targets |
|---|---|---|---|
| Turnover Growth | 3.46% | 3-5% | Sustained mid-single digit |
| Core Operating Profit Growth | - | 6-8% | Double-digit CAGR to 2026 |
| New Product Sales | ~£3B | Growing | >£12B by 2026 |
| Total Sales Target | £31.4B | £32B+ | >£40B by 2031 |
Key Growth Drivers:
Risk Factors: Key risks include regulatory delays, competition from other RSV vaccines (Abrysvo, mResvia), pricing pressure in key markets, and potential pipeline setbacks. The company also faces ongoing litigation exposure, including the Zantac cases that impacted 2024 results.
Investment Thesis: GSK offers a compelling combination of established vaccine leadership, innovative pipeline assets, and strong financial returns. The company's focus on specialty medicines and vaccines positions it well for sustainable growth, while its commitment to R&D ensures continued innovation. The successful launch of Arexvy validates GSK's ability to deliver breakthrough medicines addressing significant unmet medical needs.
Sources: GSK Annual Report 2024; GSK Financial Statements; Clinical Trial Data; Industry Analysis; Systematic Review of RSV Vaccines (PMC)
Analysis Date: January 2026